We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NNOX:NASDAQNANO-X IMAGING LTD Analysis

Data as of 2026-05-26 - not real-time

$1.84

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Nano‑X is trading at $1.84, well below its 20‑day SMA of $1.77, 50‑day SMA of $2.11 and 200‑day SMA of $3.09, indicating a deep‑seated bearish price environment. The RSI sits at 47, suggesting neutral momentum, while the MACD shows a modest bullish histogram (+0.04) but the line remains negative, reinforcing a cautious outlook. Volatility is extreme at >114% over the past 30 days and beta is 1.72, amplifying price swings, and the stock has suffered a historic drawdown of over 71%. Valuation metrics point to a potential bargain: price‑to‑book is 0.92, upside/downside is quoted at +291%, and the Fear‑Greed Index reads “Extreme Greed,” hinting at speculative enthusiasm despite weak fundamentals.
Fundamentally, the company posts a negative gross margin (‑98%) and operating margin (‑4.8%), with no earnings and a trailing EPS of –1.16, yet it holds $59.6 M in cash against $7.85 M of debt, providing a modest runway. Recent news highlights a string of U.S. distribution agreements that could seed commercial traction, but multiple securities‑fraud investigations by law firms add a significant legal cloud. The analyst consensus is a “strong buy,” but only three analysts contribute, underscoring limited coverage.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price below all major moving averages
  • ongoing securities‑fraud investigations
  • decreasing volume and high volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • new multi‑year distribution and deployment agreements
  • substantial cash buffer relative to debt
  • significant upside potential relative to book value

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • large addressable market for AI‑enabled imaging
  • potential FDA clearances and broader regulatory approvals
  • strategic positioning in teleradiology and cloud‑based services

Key Metrics & Analysis

Financial Health

Revenue Growth24.00%
P/E Ratio-9.2
ROE-45.62%
ROA-20.37%
Debt/Equity5.62
P/B Ratio0.9
Op. Cash Flow$-40793000
Free Cash Flow$-25294250
Industry P/E27.6

Technical Analysis

TrendBearish
RSI47.2
Support$1.59
Resistance$1.97
MA 20$1.77
MA 50$2.11
MA 200$3.09
MACDBullish
VolumeDecreasing
Fear & Greed Index91.63

Valuation

Target Price$7.20
Upside/Downside291.30%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.72
Volatility114.51%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.